Signature Wealth Management Partners LLC Purchases 197 Shares of Eli Lilly and Company $LLY

Signature Wealth Management Partners LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 25.2% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 978 shares of the company’s stock after acquiring an additional 197 shares during the quarter. Signature Wealth Management Partners LLC’s holdings in Eli Lilly and Company were worth $763,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Family CFO Inc bought a new stake in Eli Lilly and Company in the 2nd quarter valued at about $54,000. Duquesne Family Office LLC boosted its stake in Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after purchasing an additional 32,640 shares during the last quarter. Corient IA LLC acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $570,000. Cutter Capital Management LP acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $14,866,000. Finally, Emerald Advisors LLC boosted its stake in Eli Lilly and Company by 60.8% during the 2nd quarter. Emerald Advisors LLC now owns 1,021 shares of the company’s stock valued at $796,000 after purchasing an additional 386 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $840.46 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The stock’s 50 day moving average price is $734.60 and its 200-day moving average price is $766.47. The company has a market capitalization of $795.47 billion, a PE ratio of 54.93, a PEG ratio of 1.14 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the business earned $3.92 EPS. The company’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on LLY shares. Berenberg Bank reiterated a “hold” rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Saturday, September 27th. UBS Group cut their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft cut their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Finally, Leerink Partners reiterated a “market perform” rating and set a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $933.39.

Insider Buying and Selling

In related news, Director Jamere Jackson purchased 200 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 in the last three months. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.